AlphAIalphai — Financial news for AI agents
Simply Wall StreetMAR 273 min read$BTMD

biote (BTMD) Balance Sheet & Financial Health Metrics

This article provides an overview of biote (BTMD)'s financial health and balance sheet metrics. It highlights key figures such as a negative shareholder equity of $-50.4M and total debt of $107.0M, resulting in a debt-to-equity ratio of -212.4%. The company's EBIT is $35.1M, with an interest coverage ratio of 3.2, and it holds $24.1M in cash and short-term investments.

Original reporting
Simply Wall Street
Published Mar 27, 2026, 6:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 27, 2026, 6:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$BTMD
Bearish
medium confidence
Mentioned
$BTMD
alphai data visualization · based on Simply Wall Street
Decision brief

The 30-second read

$BTMDBearishLow
01

Why it matters

The negative equity and high debt levels could lead to increased stock volatility and potential downside risk.

02

Market read

The financial health concerns are specific to BTMD but may influence investor sentiment in the biotech sector.

03

What to watch

Potential upcoming catalysts such as drug approvals or partnerships could alter the financial outlook positively.

Timing: medium-term

Background

Biote (BTMD) is a biotech company with recent financial disclosures indicating significant balance sheet challenges.

Company-level read

Ticker impact

$BTMDBearishMedium confidence
Context

The article discusses biote (BTMD)'s financial health, highlighting significant balance sheet concerns.

Expected impact

Potential downward pressure on stock price due to financial instability; short-term volatility may increase.

Evidence & confidence

The negative shareholder equity and high debt levels suggest financial weakness, which could lead to a decline in stock price. However, positive EBIT and interest coverage indicate some operational stability, tempering the overall negative outlook.

Market effects

Sector

The biotech sector may experience increased scrutiny and cautious trading due to financial distress signals from companies like BTMD.

Regional

Limited regional impact; concerns are company-specific rather than sector-wide.

Global

Minimal; the news is specific to BTMD and does not indicate broader global market implications.

Counterpoint

What could challenge this read

Some investors may view the company's operational profitability (EBIT) as a sign of potential turnaround if debt levels are managed effectively.

Key entities

  • Company
    Biote (BTMD)

    A biotech firm with recent financial struggles as highlighted in the article.

Read at source← All news

Related articles

AUG 7
$BTMDMed

biote Q2 Earnings Call Highlights

Biote (NASDAQ: BTMD) reported Q2 net loss of $7.4M ($0.23/share) versus prior-year net income of $3.9M, and adjusted EBITDA of $5.6M (12.6% margin). Gross margin fell to 65.4% from 71.6% due to higher-cost third-party pellets during a disruption and $600k recall-related costs. Biote cut its 2026 outlook to revenue above $175M and adjusted EBITDA above $25M.

yahoo.com6 min
AUG 5
$BTMDMed

biote Corp. (BTMD): Results of Operations and Financial Condition

biote Corp. (BTMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 btmd-ex99_1.htm EX-99.1 EX-99.1 Biote Reports Second Quarter 2026 Financial Results Continued progress in advancing strategic initiatives Updates full-year outlook Second Quarter 2026 Financial Highlights • Revenue of $44.2 million • Gross profit margin of 65.4% • Net l

SEC EDGAR 8-K6 min
AUG 8
$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).

fool.com6 min
AUG 8
$SUNEMedAI 8/10

Pentagon to invest $400m in Australian rare earth mine

Sunrise Energy Metals said the US Pentagon will provide a conditional $400 million loan commitment to develop Syerston, a proposed scandium mine in Fifield, NSW. The project targets Western supply of scandium used in defence and other sectors amid China’s export restrictions. Sunrise also said it has a deal with Lockheed Martin for 25% of output for five years.

bssnews.net4 min
AUG 8
$APLDMedAI 8/10

APLD Stock Rallies After Hours On Massive New $7.5 Billion Hyperscaler Lease: Retail Think Firm Should Be Worth More Than Rival IREN

Applied Digital (APLD) shares rose more than 7% after hours after the company said it surpassed 1 GW of contracted capacity for its AI data centers. It signed a 15-year take-or-pay lease for Polaris Forge 3 with a U.S. investment-grade hyperscaler, valued at about $7.5B base-term contracted revenue and up to $18.2B with renewals. Total contracted lease revenue across four campuses is $31B.

stocktwits.com4 min